medigraphic.com

2017, Number S1

<< Back Next >>

Rev Mex Anest 2017; 40 (S1)

Old drugs, new tricks. Propanidide in Mexico: myths and realities

Barraza-Espinoza V

Language: Spanish
References: 54
Page: 79-89
PDF size: 260.61 Kb.


Text Extraction

No abstract.


REFERENCES

  1. Muñoz-Cuevas JH. TIVA: Papel en la anestesia moderna. Rev Mex Anest. 2006;29:S141-S147.

  2. Rodríguez de la Fuente-Mora F, Mora-Arévalo S. Empleo del nuevo anestésico endovenoso éster n-propílico del ácido 3-metoxi-4-n-n-dietil-carbamido-metoxi-fenilácetico Bayer 1420. Reporte preliminar. Instituto Mexicano del Seguro Social (IMSS). 1980 H.G.O. No. 2 C.M.N. pág. 167-1978.

  3. Yánez-Cortés E. Hipnosedantes. Rev Mex Anest. 2004;27:S93-S94.

  4. Criollo-Muñoz FH, Muñoz-Cuevas JH. Perfusiones intravenosas en modo manual: una estrategia simplificada mediante sistemas de gravedad. Rev Mex Anest. 2014;37:S299-S304.

  5. Barraza-Espinoza V. Paper No: 1258.0: Hypnotic depth and duration measured by bispectral index with propanidid versus propofol during the curettage in abortions. Br J Anaesth. 2012;108:ii34–ii35.

  6. Casillas de G B, Ayala-Mendoza EI, Sánchez-Orozco M. Uso de propanidido en procedimientos ginecoobstétricos de corta estancia. Revista del Anestesiólogo Moderno. 2003;34-40.

  7. Christmas D. Immune reaction to propanidid. Anaesthesia. 1984;39:470-473.

  8. Deschodt J, Lubrano JF, Peschaud JL, Eledjam JJ, du Cailar J. Comparison of propofol and propanidid administered at a constant rate. Ann Fr Anesth Reanim. 1988;7:459-463.

  9. Date AA, Nagarsenker MS. Parenteral microemulsions: an overview. Int J Pharm. 2008;355:19-30.

  10. BASF. Excipiente para formulación de drogas. Kolliphor HS 15. 2012. Disponible en: https://pharmaceutical.basf.com/en/Drug-Formulation/Kolliphor-HS-15.html.

  11. Dundee JW. Anestésicos intravenosos. Mallorca, Barcelona: Salvat Editores, S.A.; 1982. pp. 1-2, 17-23.

  12. Ball C, Westhorpe R. Intravenous induction agents-propanidid. Anaesth Intensive Care. 2002;30:261.

  13. Toque Y, Fortaine MR, Delloue M, Lephay A, Khoury A, Ossart M. Intravenous anesthesia for cesarean section. Comparison of propanidid and methohexital. Agressologie. 1991;32:246-249.

  14. Deschodt J, Lubrano JF, Peschaud JL, Eledjam JJ, du Cailar J. Comparison of propofol and propanidid administered at a constant rate. Ann Fr Anesth Reanim. 1988;7:459-463.

  15. Bertrand D, Taron F, Manel J, Laxenaire MC. Propofol versus propanidid for the conduction of suspension laryngoscopy. Ann Fr Anesth Reanim. 1987;6:289-292.

  16. Gastelain PY, Piriou A. Contact dermatitis due to propanidid in an anesthetist. Contact Dermatitis. 1980;6:360.

  17. Wisborg K, Sapthavichaikul S, Skovsted P. The effects of propanidid on arterial pressure, pulse rate, preganglionic sympathetic activity and barostatic reflexes in the cat. Can Anaesth Soc J. 1977;24:505-513.

  18. Mahomedy MC, Downing JW, Jeal DE, Coleman AJ. Propanidid for anaesthetic induction at Caesarean section. S Afr Med J. 1975;49:1358-1360.

  19. Kirkness EF, Turner AJ. The gamma-aminobutyrate/benzodiazepine receptor from pig brain. Enhancement of gamma-aminobutyrate-receptor binding by the anaesthetic propanidid. Biochem J. 1986;233:259-264.

  20. Sweetman AJ, Lovett GS, Markham A, Cameron I. Effect of the general anaesthetic propanidid on oxidative phosphorylation and calcium transport in rt liver mitochondria. Biochem Pharmacol. 1981;30:1921-1924.

  21. Meraz-Suárez R, Gómez-Fuentes S, Soto-River V. Estudio comparativo con propanidido y propofol en endoscopías. Revista del Anestesiólogo Moderno. 2003;47-54.

  22. Aguilar-Gutiérrez A. Propanidida, anestésico para el paciente ambulatorio. Torreón, Coahuila: IMSS.

  23. Armando-Rivera O. Consideraciones sobre el empleo del epontol (propanidida) en la operación cesárea. Análisis clínico de 100 casos. Rev Med Hondur. 263-273.

  24. Collins VJ. Anestesiología. 2ª edición. México, D.F.: Editorial Interamericana; 1980. pp. 191-199.

  25. Piccinelli G, Angiolillo M. Intravenose narkose mit propanidid. Propanidid-infusion for anaesthesia of long duration in obstetrics. In: Zindler M, Yamamura H, Wirth W. Anaesthesiology and resuscitation epontol-symposium Vol. 10. Berlin, Heidelberg, New York: Spinger-Verlag; 1971 pp. 275-278.

  26. Barraza-Espinoza V. Comparación de la profundidad hipnótica y su duración mediante índice bispectral inducida con propanidido vs propofol durante la aspiración manual endouterina [Tesis Digital]. Morelia, Michoacán: UNAM; 2006. Disponible en: http://132.248.9.195/pd2007/0614086/Index.html

  27. Arceo-Venegas M. Respuesta hemodinámica y profundidad hipnótica (BIS) durante la inducción e intubación endotraqueal con diferentes dosis de propanidido [Tesis Digital]. Morelia, Michoacán: UNAM; 2007. Disponible en: http://132.248.9.195/pd2008/0623103/Index.html

  28. Figueroa-Rojas S. Dosis mínima de inducción y mantenimiento de propanidido guiado por BIS para la sedación durante la panendoscopía digestiva diagnostica [Tesis Digital]. Morelia, Michoacán: UNAM; 2008. Disponible en: http://132.248.9.195/ptd2008/octubre/0635400/Index.html

  29. Valdez-Ponce A. Comparación de la duración y profundidad hipnótica de propanidido vs sevoflurano, inducidas para la aplicación intratecal de quimioterapia en pacientes pediátricos [Tesis Digital]. Morelia, Michoacán: UNAM; 2008. Disponible en: http://132.248.9.195/ptd2008/octubre/0635420/Index.html

  30. Obregón-Corona A. Cambios en la oximetría regional cerebral en paciente que reciben propanidido versus tiopental sódico durante la terapia electroconvulsiva [Tesis Digital]. México, D.F.: UNAM; 2003. Disponible en: http://132.248.9.195/ppt2002/0324550/Index.html

  31. Aveling W, Bradshaw AD, Crankshaw DP. The effect of speed of injection on the potency of anaesthetic induction agents. Anaesth Intensive Care. 1978;6:116-119.

  32. Carrillo-García F. Diferencias en los cambios hemodinámicos, durante la inducción anestésica propanidod vs propofol [Tesis Digital]. Hermosillo, Sonora: UNAM; 2005. Disponible en: http://132.248.9.195/pdtestdf/0352076/Index.html

  33. Sneyd JR. Recent advances in intravenous anaesthesia. Br J Anaesth. 2004;93:725-736.

  34. Jenkins T, Beattie D, Jaw-Tsai S, Amagasu S, Halladay J, Vanapalli S, et al. THRX-918661, a novel, pharmacokinetically responsive sedative/hypnotic agent. Anaesthesia. 2004;59:100.

  35. Egan TD, Shafer SL, Jenkins TE, Beatie DT, Jaw-Tsai SS. The pharmacokinetics and pharmacodynamics of THRX-918661, a novel sedative/hypnotic agent. Anesthesiology. 2003;99:A-516.

  36. Egan TD. Is anesthesiology going soft?: trends in fragile pharmacology. Anesthesiology. 2009;111:229-230.

  37. Feldman PL, James MK, Brackeen MF, Bilotta JM, Schuster SV, Lahey AP, et al. Design, synthesis, and pharmacological evaluation of ultrashort- to long-acting opioid analgetics. J Med Chem. 1991;34:2202-2208.

  38. Egan TD, Lemmens HJ, Fiset P, Hermann DJ, Muir KT, Stanski DR, et al. The pharmacokinetics of the new short-acting opioid remifentanil (GI87084B) in healthy adult male volunteers. Anesthesiology. 1993;79:881-892.

  39. Sneyd JR, Rigby-Jones AE. New drugs and technologies, intravenous anaesthesia is on the move (again). Br J Anaesth. 2010;105:246-254.

  40. Scott RP, Saunders DA, Norman J. Propofol: clinical strategies for preventing the pain of injection. Anaesthesia. 1988;43:492-494.

  41. Rau J, Roizen MF, Doenicke AW, O’Connor MF, Strohschneider U. Propofol in an emulsion of long- and medium-chain triglycerides: the effect on pain. Anesth Analg. 2001;93:382-384, 3rd contents page.

  42. Thomas DV. Propofol supports bacterial growth. Br J Anaesth. 1991;66:274.

  43. Cremer OL, Moons KG, Bouman EA, Kruijswijk JE, de Smet AM, Kalkman CJ. Long-term propofol infusion and cardiac failure in adult head-injured patients. Lancet. 2001;357:117-118.

  44. Bray RJ. Propofol infusion syndrome in children. Paediatr Anaesth. 1998;8:491-499.

  45. Sneyd JR. Excitatory events associated with propofol anaesthesia: a review. J R Soc Med. 1992;85:288-291.

  46. Tuk B, van Oostenbruggen MF, Herben VM, Mandema JW, Danhof M. Characterization of the pharmacodynamic interaction between parent drug and active metabolite in vivo: midazolam and alpha-OH-midazolam. J Pharmacol Exp Ther. 1999;289:1067-1074.

  47. Kilpatrick GJ, Tilbrook GS. Drug development in anaesthesia: industrial perspective. Curr Opin Anaesthesiol. 2006;19:385-389.

  48. Ball C, Westhorpe R. Intravenous induction agents-propanidid. Anaesth Intensive Care. 2002;30:261.

  49. Egan TD, Obara S, Jenkins TE, Jaw-Tsai SS, Amagasu S, Cook DR, et al. AZD-3043: a novel, metabolically labile sedative-hypnotic agent with rapid and predictable emergence from hypnosis. Anesthesiology. 2012;116:1267-1277.

  50. Kalman S, Koch P, Ahlén K, Kanes SJ, Barassin S, Björnsson MA, et al. First human study of the investigational sedative and anesthetic drug AZD3043: a dose-escalation trial to assess the safety, pharmacokinetics, and efficacy of a 30-minute infusion in healthy male volunteers. Anesth Analg. 2015;121:885-893.

  51. Norberg Å, Koch P, Kanes SJ, Björnsson MA, Barassin S, Ahlén K, et al. A bolus and bolus followed by infusion study of AZD3043, an investigational intravenous drug for sedation and anesthesia: safety and pharmacodynamics in healthy male and female volunteers. Anesth Analg. 2015;121:894-903.

  52. Björnsson MA, Norberg Å, Kalman S, Simonsson US. A Recirculatory Model for pharmacokinetics and the effects on bispectral index after intravenous infusion of the sedative and anesthetic AZD3043 in healthy volunteers. Anesth Analg. 2015;121:904-913.

  53. White PF. Clinical uses of intravenous anesthetic and analgesic infusions. Anesth Analg. 1989;68:161-171.

  54. Zhang H, Xu X, Chen Y, Qiu Y, Liu X, Liu BF, et al. Synthesis and evaluation of fluorine-substituted phenyl acetate derivatives as ultra-short recovery sedative/hypnotic agents. PLoS One. 2014;9:e96518.




2020     |     www.medigraphic.com